ArticleCancer immunology, immunotherapy : CII2023

Effectiveness and tolerability of camrelizumab combined with molecular targeted therapy for patients with unresectable or advanced HCC.

Ting Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.